Targeted Delivery of Immune Agonists for Antitumoral Response of the Tumor Microenvironment
JSHS · 2020
Overview
Tumor-mediated immunosuppression allows tumors to hide from the immune system and avoid recognition. To reverse this suppressive microenvironment, antigen-presenting cells (APCs) and other innate/adaptive immune cells within the tumor can be targeted and activated from their senescent states. Cyclic diguanylate monophosphate (c-di-GMP), a drug that works within the cytosol of immune cells, is used to release inflammatory cytokines (IFN-) to recruit immune cells and initiate anti-tumor responses. However, therapy using freely injected drug is limited because c-di-GMP cannot easily cross cell membranes and is quickly cleared from the body. It is hypothesized that c-di-GMP loaded into a nanoparticle will more effectively deliver drug into the cytosol of immune cells, widespread within the tumor, resulting in more potent therapy. To demonstrate the therapeutic potential, macrophages were exposed to c-di-GMP loaded into nanoparticles in vitro. C-di-GMP nanoparticles boosted the secretion of cytokine IFN- from murine macrophages by 6-fold compared to free drug. To increase the particle specificity for suppressive immune cells, an antibody targeting the novel inhibitory immune-checkpoint protein V- domain Immunoglobulin Suppressor of Tcell Activation (VISTA) was conjugated to the surface of a nanoparticle. Ongoing work looks to demonstrate the increased uptake of VISTA-targeting particles by a VISTA expressing cell line in vitro. This work demonstrates a potential new treatment that increases the efficacy of c -di- GMP by targeting and reversing immunosuppressive cell subtypes. Future work includes in vitro and in vivo studies optimizing the delivery of nanoparticles to tumor-associated immune cells and evaluating the therapeutic effects on tumor burden and overall survival.
Awards (1)
- 1st Place Biomedical Sciences
Competition history
- JSHS 2020
Resources
Related projects
ISEF · 2020
Targeted Delivery of Immune Agonists for Antitumoral Response of the Tumor Microenvironment
ISEF · 2019
Site-Specific Delivery of Immune Agonists for Antitumoral Response of the Tumor Microenvironment
ISEF · 2021
Removing Brakes of Tumor-Resident Myeloid Cells as a Novel Cancer Immunotherapy
ISEF · 2015
Development of a Nanoparticle for Targeted Antigen Delivery as a Therapeutic Vaccination Platform
ISEF · 2019
Reversing Tumor-Induced T Cell Suppression through Activation of TLR8 Pathway
ISEF · 2019
Priming the Tumor Microenvironment with Cyclophosphamide to Enhance Nanoparticle Delivery: An Imaging Study
JSHS · 2025
Design and Characterization of Novel Imatinib-Loaded Nanoparticles for Localized Immunomodulation
ISEF · 2022
BG34-200 Engagement With Integrin CD11b for Modulating Tumor-Associated Myeloid Cells in Pancreatic Cancer
Closest projects by meaning, across every fair and year in the corpus.